Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein
Hideko Kasahara, … , Charles I. Berul, Seigo Izumo
Hideko Kasahara, … , Charles I. Berul, Seigo Izumo
Published July 15, 2001
Citation Information: J Clin Invest. 2001;108(2):189-201. https://doi.org/10.1172/JCI12694.
View: Text | PDF
Article

Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein

  • Text
  • PDF
Abstract

A DNA nonbinding mutant of the NK2 class homeoprotein Nkx2.5 dominantly inhibits cardiogenesis in Xenopus embryos, causing a small heart to develop or blocking heart formation entirely. Recently, ten heterozygous CSX/NKX2.5 homeoprotein mutations were identified in patients with congenital atrioventricular (AV) conduction defects. All four missense mutations identified in the human homeodomain led to markedly reduced DNA binding. To examine the effect of a DNA binding–impaired mutant of mouse Csx/Nkx2.5 in the embryonic heart, we generated transgenic mice expressing one such allele, I183P, under the β-myosin heavy chain promoter. Unexpectedly, transgenic mice were born apparently normal, but the accumulation of Csx/Nkx2.5(I183P) mutant protein in the embryo, neonate, and adult myocardium resulted in progressive and profound cardiac conduction defects and heart failure. P-R prolongation observed at 2 weeks of age rapidly progressed into complete AV block as early as 4 weeks of age. Expression of connexins 40 and 43 was dramatically decreased in the transgenic heart, which may contribute to the conduction defects in the transgenic mice. This transgenic mouse model may be useful in the study of the pathogenesis of cardiac dysfunction associated with CSX/NKX2.5 mutations in humans.

Authors

Hideko Kasahara, Hiroko Wakimoto, Margaret Liu, Colin T. Maguire, Kimber L. Converso, Tetsuo Shioi, Weei-Yuarn Huang, Warren J. Manning, David Paul, Joel Lawitts, Charles I. Berul, Seigo Izumo

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Reduced expression of connexin 43 in the TG heart. (a) Northern blot ana...
Reduced expression of connexin 43 in the TG heart. (a) Northern blot analysis of connexin 43 from neonatal stage to 3 weeks of age. Connexin 43 mRNA expression was similar between NTG (lane 1) and TG (lane 2) at the neonatal stage, but gradually decreased in the TG mouse heart (compare lane 3 vs. 4, lane 5 vs. 6, and lane 7 vs. 8). Connexin 43 transcript in TG mice was barely detectable at 3 weeks of age (lane 8). GAPDH expression is also shown. (b) Connexin 43 downregulation was heart specific. Northern blot analysis of connexin 43 in brain, heart, and skeletal muscle. GAPDH expression is also shown. (c) Western blot analysis of connexin 43 in the TG ventricle at 3 and 6 weeks from two different TG lines (numbers 25 and 33), compared with NTG ventricles. Connexin 43 protein expression was markedly reduced in no. 25 line and moderately reduced in no. 33 line. Troponin T expression was also shown. (d–k) Immunofluorescent staining of connexin 43 (FITC) and sarcomeric actinin (rhodamine; merged image in f, g, j, k) in atrium (A; d–g) and ventricle (V; h–k) at 3 weeks, and neonates of NTG and TG mice. (d and f) Connexin 43 staining (FITC) was observed in the NTG atrium (arrows) localized in cell-cell junctions, whereas connexin 43 expression in the TG atrium was occasionally detectable (e and g). Note ventricular expression of connexin 43 (FITC) in NTG heart (h and j) compared with TG heart (i and k). Bars, 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts